Trade Paratek Pharma - PRTK CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Paratek Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.17 |
Open* | 2.17 |
1-Year Change* | -12.15% |
Day's Range* | 2.17 - 2.22 |
52 wk Range | 1.29-3.65 |
Average Volume (10 days) | 341.85K |
Average Volume (3 months) | 11.48M |
Market Cap | 127.26M |
P/E Ratio | -100.00K |
Shares Outstanding | 57.32M |
Revenue | 177.00M |
EPS | -1.11 |
Dividend (Yield %) | N/A |
Beta | 1.69 |
Next Earnings Date | Nov 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 20, 2023 | 2.22 | 0.05 | 2.30% | 2.17 | 2.22 | 2.17 |
Sep 19, 2023 | 2.17 | 0.00 | 0.00% | 2.17 | 2.17 | 2.16 |
Sep 18, 2023 | 2.16 | -0.01 | -0.46% | 2.17 | 2.18 | 2.16 |
Sep 15, 2023 | 2.17 | -0.01 | -0.46% | 2.18 | 2.18 | 2.16 |
Sep 14, 2023 | 2.17 | -0.01 | -0.46% | 2.18 | 2.18 | 2.17 |
Sep 13, 2023 | 2.18 | -0.01 | -0.46% | 2.19 | 2.19 | 2.18 |
Sep 12, 2023 | 2.19 | 0.00 | 0.00% | 2.19 | 2.19 | 2.19 |
Sep 11, 2023 | 2.18 | -0.01 | -0.46% | 2.19 | 2.20 | 2.18 |
Sep 8, 2023 | 2.19 | 0.01 | 0.46% | 2.18 | 2.19 | 2.18 |
Sep 7, 2023 | 2.19 | 0.01 | 0.46% | 2.18 | 2.19 | 2.18 |
Sep 6, 2023 | 2.18 | 0.01 | 0.46% | 2.17 | 2.19 | 2.17 |
Sep 5, 2023 | 2.18 | 0.01 | 0.46% | 2.17 | 2.19 | 2.17 |
Sep 1, 2023 | 2.17 | -0.02 | -0.91% | 2.19 | 2.20 | 2.17 |
Aug 31, 2023 | 2.19 | 0.02 | 0.92% | 2.17 | 2.19 | 2.17 |
Aug 30, 2023 | 2.18 | 0.01 | 0.46% | 2.17 | 2.20 | 2.17 |
Aug 29, 2023 | 2.18 | 0.01 | 0.46% | 2.17 | 2.18 | 2.17 |
Aug 28, 2023 | 2.17 | 0.01 | 0.46% | 2.16 | 2.18 | 2.16 |
Aug 25, 2023 | 2.18 | 0.01 | 0.46% | 2.17 | 2.19 | 2.17 |
Aug 24, 2023 | 2.18 | 0.02 | 0.93% | 2.16 | 2.18 | 2.16 |
Aug 23, 2023 | 2.16 | 0.00 | 0.00% | 2.16 | 2.16 | 2.16 |
Paratek Pharma Events
Time (UTC) | Country | Event |
---|---|---|
Thursday, March 14, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q4 2023 Paratek Pharmaceuticals Inc Earnings Release Q4 2023 Paratek Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 160.268 | 130.162 | 46.924 | 16.544 | 17.117 |
Revenue | 160.268 | 130.162 | 46.924 | 16.544 | 17.117 |
Total Operating Expense | 206.477 | 171.292 | 124.796 | 132.173 | 121.202 |
Selling/General/Admin. Expenses, Total | 145.398 | 119.004 | 89.355 | 89.135 | 63.658 |
Research & Development | 37.823 | 30.353 | 23.922 | 39.554 | 57.508 |
Interest Expense (Income) - Net Operating | 0 | -0.071 | |||
Unusual Expense (Income) | 0 | 2.368 | 0 | 0.107 | |
Operating Income | -46.209 | -41.13 | -77.872 | -115.629 | -104.085 |
Interest Income (Expense), Net Non-Operating | -17.367 | -17.342 | -18.725 | -12.829 | -7.725 |
Other, Net | 0.067 | -0.012 | 0.056 | -0.031 | -0.044 |
Net Income Before Taxes | -63.509 | -58.484 | -96.541 | -128.489 | -111.854 |
Net Income After Taxes | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Net Income Before Extra. Items | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Net Income | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Income Available to Common Incl. Extra. Items | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Diluted Net Income | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Diluted Weighted Average Shares | 54.3879 | 48.4155 | 44.1748 | 32.7919 | 31.5135 |
Diluted EPS Excluding Extraordinary Items | -1.16875 | -1.22035 | -2.18543 | -3.92749 | -3.56533 |
Diluted Normalized EPS | -1.16875 | -1.22035 | -2.13183 | -3.92749 | -3.56313 |
Cost of Revenue, Total | 23.056 | 21.535 | 8.651 | 3.484 | |
Gross Profit | 137.212 | 108.627 | 38.273 | 13.06 | |
Depreciation / Amortization | 0.2 | 0.4 | 0.5 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 39.993 | 31.236 | 75.557 | 30.213 | 29.637 |
Revenue | 39.993 | 31.236 | 75.557 | 30.213 | 29.637 |
Cost of Revenue, Total | 4.368 | 6.244 | 10.312 | 4.372 | 4.878 |
Gross Profit | 35.625 | 24.992 | 65.245 | 25.841 | 24.759 |
Total Operating Expense | 49.404 | 47.041 | 78.394 | 46.704 | 42.805 |
Selling/General/Admin. Expenses, Total | 36.264 | 33.489 | 53.814 | 33.846 | 30.335 |
Research & Development | 8.772 | 7.308 | 14.268 | 8.486 | 7.592 |
Operating Income | -9.411 | -15.805 | -2.837 | -16.491 | -13.168 |
Interest Income (Expense), Net Non-Operating | -5.035 | -4.255 | -4.231 | -4.35 | -4.413 |
Other, Net | -0.056 | -0.022 | -0.032 | -0.039 | -0.038 |
Net Income Before Taxes | -14.502 | -20.082 | -7.1 | -20.88 | -17.619 |
Net Income After Taxes | -14.553 | -20.143 | -7.157 | -20.88 | -17.619 |
Net Income Before Extra. Items | -14.553 | -20.143 | -7.157 | -20.88 | -17.619 |
Net Income | -14.553 | -20.143 | -7.157 | -20.88 | -17.619 |
Income Available to Common Excl. Extra. Items | -14.553 | -20.143 | -7.157 | -20.88 | -17.619 |
Income Available to Common Incl. Extra. Items | -14.553 | -20.143 | -7.157 | -20.88 | -17.619 |
Diluted Net Income | -14.553 | -20.143 | -7.157 | -20.88 | -17.619 |
Diluted Weighted Average Shares | 57.2822 | 56.9034 | 55.7513 | 55.1665 | 53.0233 |
Diluted EPS Excluding Extraordinary Items | -0.25406 | -0.35399 | -0.12837 | -0.37849 | -0.33229 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -0.25406 | -0.35399 | -0.12837 | -0.37849 | -0.33229 |
Unusual Expense (Income) |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 136.842 | 152.1 | 164.117 | 243.354 | 255.243 |
Cash and Short Term Investments | 34.248 | 95.474 | 125.162 | 215.379 | 250.351 |
Cash & Equivalents | 34.248 | 80.367 | 105.157 | 102.302 | 46.987 |
Short Term Investments | 0 | 15.107 | 20.005 | 113.077 | 203.364 |
Total Receivables, Net | 78.038 | 33.117 | 15.733 | 9.583 | 0.249 |
Accounts Receivable - Trade, Net | 78.038 | 33.117 | 15.733 | 9.583 | 0.249 |
Prepaid Expenses | 7.866 | 12.364 | 7.776 | 6.489 | 4.377 |
Other Current Assets, Total | 0.125 | 0.125 | 0.891 | 0.324 | 0.266 |
Total Assets | 172.538 | 183.869 | 176.853 | 251.079 | 300.192 |
Property/Plant/Equipment, Total - Net | 2.398 | 2.551 | 2.974 | 3.741 | 1.173 |
Property/Plant/Equipment, Total - Gross | 4.874 | 4.814 | 5.761 | 6.077 | 2.985 |
Accumulated Depreciation, Total | -2.476 | -2.263 | -2.787 | -2.336 | -1.812 |
Goodwill, Net | 0.829 | 0.829 | 0.829 | 0.829 | 0.829 |
Intangibles, Net | 0 | ||||
Other Long Term Assets, Total | 32.469 | 28.389 | 8.933 | 3.155 | 0.46 |
Total Current Liabilities | 37.388 | 31.297 | 23.953 | 24.2 | 17.709 |
Accounts Payable | 5.308 | 5.394 | 1.813 | 4.116 | 2.09 |
Accrued Expenses | 31.71 | 24.046 | 21.626 | 17.696 | 15.619 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.37 | 1.857 | 0.514 | 2.388 | |
Total Liabilities | 343.58 | 311.656 | 279.113 | 290.726 | 252.614 |
Total Long Term Debt | 256.946 | 254.428 | 250.474 | 260.728 | 228.959 |
Long Term Debt | 256.946 | 254.428 | 250.474 | 260.728 | 228.959 |
Other Liabilities, Total | 49.246 | 25.931 | 4.686 | 5.798 | 5.946 |
Total Equity | -171.042 | -127.787 | -102.26 | -39.647 | 47.578 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | |||
Common Stock | 0.056 | 0.052 | 0.046 | 0.04 | 0.032 |
Additional Paid-In Capital | 759.351 | 739.053 | 705.489 | 671.497 | 630.142 |
Retained Earnings (Accumulated Deficit) | -930.449 | -866.883 | -807.799 | -711.258 | -582.468 |
Other Equity, Total | 0 | -0.009 | 0.004 | 0.074 | -0.128 |
Total Liabilities & Shareholders’ Equity | 172.538 | 183.869 | 176.853 | 251.079 | 300.192 |
Total Common Shares Outstanding | 56.6516 | 51.7118 | 46.5166 | 39.8278 | 32.2594 |
Long Term Investments | 0 | 42.487 | |||
Total Inventory | 16.565 | 11.02 | 14.555 | 11.579 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 111.014 | 136.842 | 121.341 | 127.768 | 133.282 |
Cash and Short Term Investments | 45.026 | 34.248 | 57.009 | 69.391 | 79.053 |
Cash & Equivalents | 45.026 | 34.248 | 27.087 | 39.505 | 49.033 |
Short Term Investments | 0 | 29.922 | 29.886 | 30.02 | |
Total Receivables, Net | 37.166 | 78.038 | 32.739 | 31.818 | 28.259 |
Accounts Receivable - Trade, Net | 37.166 | 78.038 | 32.739 | 31.818 | 28.259 |
Total Inventory | 13.989 | 16.565 | 20.75 | 13.083 | 12.732 |
Prepaid Expenses | 14.708 | 7.866 | 10.718 | 13.476 | 12.988 |
Other Current Assets, Total | 0.125 | 0.125 | 0.125 | 0 | 0.25 |
Total Assets | 150.828 | 172.538 | 157.321 | 163.695 | 170.157 |
Property/Plant/Equipment, Total - Net | 2.24 | 2.398 | 1.791 | 2.064 | 2.298 |
Goodwill, Net | 0.829 | 0.829 | 0.829 | 0.829 | 0.829 |
Other Long Term Assets, Total | 36.745 | 32.469 | 33.36 | 33.034 | 33.748 |
Total Current Liabilities | 32.745 | 37.388 | 38.976 | 30.1 | 28.837 |
Accounts Payable | 5.318 | 5.308 | 8.107 | 2.257 | 4.697 |
Accrued Expenses | 26.633 | 31.71 | 29.22 | 26.361 | 22.733 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0.794 | 0.37 | 1.649 | 1.482 | 1.407 |
Total Liabilities | 339.866 | 343.58 | 323.473 | 313.062 | 310.459 |
Total Long Term Debt | 257.695 | 256.946 | 258.482 | 257.153 | 255.949 |
Long Term Debt | 257.695 | 256.946 | 258.482 | 257.153 | 255.949 |
Other Liabilities, Total | 49.426 | 49.246 | 26.015 | 25.809 | 25.673 |
Total Equity | -189.038 | -171.042 | -166.152 | -149.367 | -140.302 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.057 | 0.056 | 0.055 | 0.055 | 0.053 |
Additional Paid-In Capital | 761.497 | 759.351 | 757.202 | 753.223 | 744.618 |
Retained Earnings (Accumulated Deficit) | -950.592 | -930.449 | -923.292 | -902.412 | -884.793 |
Other Equity, Total | 0 | -0.117 | -0.233 | -0.18 | |
Total Liabilities & Shareholders’ Equity | 150.828 | 172.538 | 157.321 | 163.695 | 170.157 |
Total Common Shares Outstanding | 57.2822 | 56.6516 | 55.4387 | 54.7786 | 53.0233 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -63.566 | -59.084 | -96.541 | -128.79 | -112.356 |
Cash From Operating Activities | -66.141 | -48.273 | -103.424 | -134.045 | -81.179 |
Cash From Operating Activities | 0.49 | 0.391 | 0.578 | ||
Non-Cash Items | 17.726 | 18.609 | 12.825 | 16.483 | 27.254 |
Cash Interest Paid | 11.91 | 13.144 | 22.703 | 15.96 | 9.31 |
Changes in Working Capital | -20.791 | -8.189 | -20.286 | -21.738 | 3.923 |
Cash From Investing Activities | 14.804 | 4.51 | 92.499 | 134.554 | -127.874 |
Capital Expenditures | -0.036 | -0.373 | -0.376 | -0.239 | -0.06 |
Other Investing Cash Flow Items, Total | 14.84 | 4.883 | 92.875 | 134.793 | -127.814 |
Cash From Financing Activities | 5.093 | 18.332 | 11.34 | 57.622 | 220.727 |
Financing Cash Flow Items | 0.646 | ||||
Issuance (Retirement) of Stock, Net | 7.335 | 19.048 | 22.623 | 27.068 | 51.803 |
Issuance (Retirement) of Debt, Net | -2.888 | -0.716 | -11.283 | 30.554 | 168.924 |
Net Change in Cash | -46.244 | -25.431 | 0.415 | 58.131 | 11.674 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -20.143 | -63.566 | -56.409 | -35.527 | -17.91 |
Cash From Operating Activities | 11.09 | -66.141 | -46.028 | -33.609 | -19.11 |
Cash From Operating Activities | 0.047 | 0.49 | 0.404 | 0.275 | 0.144 |
Non-Cash Items | 3.175 | 17.726 | 14.39 | 9.079 | 3.99 |
Cash Interest Paid | 1.934 | 11.91 | 6.779 | 5.739 | 1.181 |
Changes in Working Capital | 28.011 | -20.791 | -4.413 | -7.436 | -5.334 |
Cash From Investing Activities | -0.032 | 14.804 | -15.196 | -15.196 | -15.196 |
Capital Expenditures | -0.032 | -0.036 | -0.036 | -0.036 | -0.036 |
Other Investing Cash Flow Items, Total | 0 | 14.84 | -15.16 | -15.16 | -15.16 |
Cash From Financing Activities | -0.28 | 5.093 | 7.819 | 7.818 | 3.097 |
Issuance (Retirement) of Stock, Net | 0 | 7.335 | 7.819 | 7.818 | 3.097 |
Issuance (Retirement) of Debt, Net | -0.28 | -2.888 | 0 | 0 | 0 |
Net Change in Cash | 10.778 | -46.244 | -53.405 | -40.987 | -31.209 |
Financing Cash Flow Items | 0.646 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Paratek Pharma Company profile
About Paratek Pharmaceuticals Inc
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel life-saving therapies for life-threatening diseases. The Company's product include NUZYRA (omadacycline) is an oral and intravenous antibiotic for the treatment of community-acquired bacterial pneumonia and acute skin and skin structure infections caused by susceptible pathogens. Its other product includes SEYSARA, which is a oral therapy for the treatment of moderate to severe acne vulgaris.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Paratek Pharmaceuticals Inc revenues increased from $46.9M to $130.2M. Net loss decreased 39% to $59.1M. Revenues reflect Product revenue, net increase from $38.8M to $106.1M, Collaboration and royalty revenue increase from $1.5M to $8.2M, Government contract grant revenue increase from $3.4M to $9.2M. Lower net loss reflects Interest Expense decrease of 14% to $17.4M (expense).
Equity composition
Common Stock $.001 Par, 3/11, 100M auth., 13,467,933 issd. Insiders control 9.22%. IPO: 5/06 .3M shs. @ $6.50 per share by Bear, Stearns & Co. Inc. 02/09, Name changed from Novacea, Inc. 02/09, 5-for-1 reverse stock split. 10/14,1-for-12 reverse stock split.
Industry: | Pharmaceuticals (NEC) |
75 Park Plaza
4th Floor
BOSTON
MASSACHUSETTS 02116
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com